Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy

BACKGROUND: Patients with programmed cell death‐ligand 1 (PD‐L1) ≥50% metastatic non‐small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first‐line immunotherapy have heterogeneous clinical assessment and outcomes. METHODS: To explore the role of immune‐inflammatory su...

Descripción completa

Detalles Bibliográficos
Autores principales: Banna, Giuseppe L., Tiseo, Marcello, Cortinovis, Diego L., Facchinetti, Francesco, Aerts, Joachim G. J. V., Baldessari, Cinzia, Giusti, Raffaele, Bria, Emilio, Grossi, Francesco, Berardi, Rossana, Morabito, Alessandro, Catino, Annamaria, Genova, Carlo, Mazzoni, Francesca, Gelibter, Alain, Rastelli, Francesca, Macerelli, Marianna, Chiari, Rita, Gori, Stefania, Mansueto, Giovanni, Citarella, Fabrizio, Cantini, Luca, Rijavec, Erika, Bertolini, Federica, Cappuzzo, Federico, De Toma, Alessandro, Friedlaender, Alex, Metro, Giulio, Pensieri, Maria Vittoria, Porzio, Giampiero, Ficorella, Corrado, Pinato, David J., Cortellini, Alessio, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807213/
https://www.ncbi.nlm.nih.gov/pubmed/34939342
http://dx.doi.org/10.1111/1759-7714.14256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807213/
https://www.ncbi.nlm.nih.gov/pubmed/34939342
http://dx.doi.org/10.1111/1759-7714.14256

Ejemplares similares